Metabolic Dysfunction-Associated Steatotic Liver Disease, Alcohol-Associated Liver Disease, and MetALD: Beyond the Nomenclature, Part 2

Description

Presenters in this 2-part session dissect the intricate relationship between metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD), and the overlapping entity MetALD. Renowned experts explore these entities in terms of epidemiology, etiology, clinical diagnostics, and therapeutic approaches. Presenters delve into whether these conditions are distinct, overlapping, or part of a disease continuum by scrutinizing molecular, histologic, and epidemiologic evidence, and discuss future directions in screening, stratification, and drug development. Join this session to: (1) gain insights into the nuances that differentiate MASLD, ALD, and MetALD and the evidence supporting a spectrum or continuum of disease; (2) expand knowledge to apply advanced diagnostic tools effectively in clinical practice; (3) hone diagnostic and therapeutic strategies; and (4) develop a deeper understanding of the treatment landscape, unmet needs, and future directions in therapy and research for these liver diseases.